Dietary supplementation of resveratrol attenuates chronic colonic inflammation in mice

European Journal of Pharmacology

Volumn 633, Issue 1-3, 2010, Pages 78-84

  Sánchez Fidalgo, Susana ^a   Cárdeno, Ana ^a   Villegas, Isabel ^a   Talero, Elena ^a   de la Lastra, Catalina Alarcón ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

Author keywords

Chronic colitis; COX 2; Cytokines; INOS; P38; Resveratrol

Indexed keywords

CYCLOOXYGENASE 2; DEXTRAN SULFATE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE P38; PROSTAGLANDIN E SYNTHASE 1; RESVERATROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC INFLAMMATION; COLITIS; COLON MUCOSA; CONTROLLED STUDY; CYTOKINE RELEASE; DIARRHEA; DIET SUPPLEMENTATION; DISEASE ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; ENZYME REGULATION; FEMALE; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECTUM HEMORRHAGE; SIGNAL TRANSDUCTION; SURVIVAL RATE; WEIGHT REDUCTION;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHRONIC DISEASE; COLITIS, ULCERATIVE; COLON; CYCLOOXYGENASE 2; CYTOKINES; DEXTRAN SULFATE; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; FEMALE; INTRAMOLECULAR OXIDOREDUCTASES; MICE; MICE, INBRED C57BL; NITRIC OXIDE SYNTHASE TYPE II; ORGAN SIZE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; STILBENES;

EID: 77949915935     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.01.025     Document Type: Article

References (54)

1. Arai Y., Takanashi H., Kitagawa H., Okayasu I. Involvement ofinterleukin-1 in the development of ulcerative colitis induced by dextransulfate sodium in mice. Cytokine 1998, 10:890-896.
2. Atreya R., Neurath M.F. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin. Rev. Allergy Immunol. 2005, 28:187-196.
3. Bertelli A.A.E. Modulatory effect of resveratrol, a natural phytoalexin, on endothelial, adhesion molecules and intracellular signal transduction. Pharm. Biol. 1998, 36:44-52.
4. Bradamante S., Barenghi L., Villa A. Cardiovascular protective effects of resveratrol. Cardiovasc. Drug Rev. 2004, 22:169-188.
5. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
6. Bujanda L., García-Barcina M., Gutiérrez-de Juan V., Bidaurrazaga J., de Luco M.F., Gutiérrez-Stampa M., Larzabal M., Hijona E., Sarasqueta C., Echenique-Elizondo M., Arenas J.I. Effect of resveratrol on alcohol-induced mortality and liver lesions in mice. BMC Gastroenterol. 2006, 6:35.
7. Bujanda L., Hijona E., Larzabal M., Beraza M., Aldazabal P., García-Urkia N., Sarasqueta C., Cosme A., Irastorza B., González A., Arenas J.I. Resveratrol inhibits nonalcoholic fatty liver disease in rats. BMC Gastroenterol. 2008, 8:40.
8. Camacho-Barquero L., Villegas I., Sánchez-Calvo J.M., Talero E., Sánchez-Fidalgo S., Motilva V., Alarcón de la Lastra C. Curcumin, a Curcuma longa constituent, acts on MAPK p38 pathway modulating COX-2 and iNOS expression in chronic experimental colitis. Int. Immunol. 2007, 7:333-342.
9. Candelario-Jalil E., de Oliveira A.C., Gräf S., Bhatia H.S., Hüll M., Muñoz E., Fiebich B.L. Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia. J. Neuroinflammation 2007, 4:25.
10. Collino M., Aragno M., Mastrocola R., Gallicchio M., Rosa A.C., Dianzani C., Danni O., Thiemermann C., Fantozzi R. Modulation of the oxidative stress and inflammatory response by PPAR-gamma agonists in the hippocampus of rats exposed to cerebral ischemia/reperfusion. Eur. J. Pharmacol. 2006, 530:70-80.
11. de la Lastra C.A., Villegas I. Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications. Mol. Nutr. Food Res. 2005, 49:405-430.
12. de la Lastra C.A., Villegas I. Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Biochem. Soc. Trans. 2007, 35:1156-1160.
13. Deniz M., Cetinel S., Kurtel H. Blood flow alterations in TNBS-induced colitis: role of endothelin receptors. Inflamm. Res. 2004, 53:329-336.
14. Dignass A.U., Podolsky D.K., Rachmilewitz D. NO chi generation by cultured small intestinal epithelial cells. Dig. Dis. Sci. 1995, 40:1859-1865.
15. Docherty J.J., Fu M.M., Tsai M. Resveratrol selectively inhibits Neisseria gonorrhoeae and Neisseria meningitidis. J Antimicrob Chemother 2001, 47:243-244.
16. Dubuquoy L., Dharancy S., Nutten S., Pettersson S., Auwerx J., Desreumaux P. Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet 2002, 360:1410-1418.
17. El Mowafy A.M., White R.E. Resveratrol inhibits MAPK activity and nuclear translocation in coronary artery smooth muscle: reversal of endothelin-1 stimulatory effects. FEBS Lett. 1999, 451:63-67.
18. Hennebert O., Pelissier M.A., Le Mee S., Wülfert E., Morfin R. Anti-inflammatory effects and changes in prostaglandin patterns induced by 7beta-hydroxy-epiandrosterone in rats with colitis. J. Steroid Biochem. Mol. Biol. 2008, 110:255-262.
19. Hommes D., van den Blink B., Plasse T., Bartelsman J., Xu C., Macpherson B., Tytgat G., Peppelenbosch M., Van Deventer S. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002, 122:7-14.
20. Ito R., Shin-Ya M., Kishida T., Urano A., Takada R., Sakagami J., Imanishi J., Kita M., Ueda Y., Iwakura Y., Kataoka K., Okanoue T., Mazda O. Interferon-gamma is causatively involved in experimental inflammatory bowel disease in mice. Clin. Exp. Immunol. 2006, 146:330-338.
21. Itzkowitz S.H. Molecular biology of dysplasia and cancer in inflammatory bowel disease. Gastroenterol. Clin. North Am. 2006, 35:553-571.
22. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., Fong H.H., Farnsworth N.R., Kinghorn A.D., Mehta R.G., Moon R.C., Pezzuto J.M. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275:218-220.
23. Kawada N., Seki S., Inoue M., Kuroki T. Effect of antioxidants, resveratrol, quercetin and N-acetylcysteine, on the functions of cultured rat hepatic stellate cells and Kupffer cells. Hepatology 1998, 27:1265-1274.
24. Kim G.Y., Kim K.H., Lee S.H., Yoon M.S., Lee H.J., Moon D.O., Lee C.M., Ahn S.C., Park Y.C., Park Y.M. Curcumin inhibits immunostimulatory function of dendritic cells: MAPKs and translocation of NF-kappa B as potential targets. J. Immunol. 2005, 174:8116-8124.
25. Kim J.M., Jung H.Y., Lee J.Y., Youn J., Lee C.H., Kim K.H. Mitogen-activated protein kinase and activator protein-1 dependent signals are essential for Bacteroides fragilis enterotoxin-induced enteritis. Eur. J. Immunol. 2005, 35:2648-2657.
26. Kim Y.A., Lim S.Y., Rhee S.H., Park K.Y., Kim C.H., Choi B.T., Lee S.J., Park Y.M., Choi Y.H. Resveratrol inhibits inducible nitric oxide synthase and cyclooxygenase-2 expression in beta-amyloid-treated C6 glioma cells. Int. J. Mol. Med. 2006, 17:1069-1075.
27. Kimura Y., Okuda H. Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice. J. Nutr. 2001, 131:1844-1849.
28. Kolios G., Valatas V., Ward S.G. Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology 2004, 113:427-437.
29. Kucharzik T., Maaser C., Lügering A., Kagnoff M., Mayer L., Targan S., Domschke W. Recent understanding of IBD pathogenesis: implications for future therapies. Inflamm. Bowel Dis. 2006, 12:1068-1083.
30. Kwon H.S., Oh S.M., Kim J.K. Glabridin, a functional compound of liquorice, attenuates colonic inflammation in mice with dextran sulphate sodium-induced colitis. Clin. Exp. Immunol. 2008, 151:165-173.
31. Kyriakis J.M., Avruch J. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 2001, 81:807-869.
32. Larrosa M., Yañéz-Gascón M.J., Selma M.V., González-Sarrías A., Toti S., Cerón J.J., Tomás-Barberán F., Dolara P., Espín J.C. Effect of a low dose of dietary resveratrol on colon microbiota, inflammation and tissue damage in a DSS-induced colitis rat model. J. Agric. Food Chem. 2009, 57:2211-2220.
33. Leiro J., Alvarez E., Arranz J.A., Laguna R., Uriarte E., Orallo F. Effects of cis-resveratrol on inflammatory murine macrophages: antioxidant activity and down-regulation of inflammatory genes. J. Leukoc. Biol. 2004, 75:1156-1165.
34. Mahady G.B., Pendland S.L., Chadwick L.R. Resveratrol and red wine extracts inhibit the growth of CagA+ strains of Helicobacter pylori in vitro. Am. J. Gastroenterol. 2003, 98:1440-1441.
35. Martín A.R., Villegas I., La Casa C., de la Lastra C.A. Resveratrol, a polyphenol found in grapes, suppresses oxidative damage and stimulates apoptosis during early colonic inflammation in rats. Biochem. Pharmacol. 2004, 67:1399-1410.
36. Martín A.R., Villegas I., Sánchez-Hidalgo M., de la Lastra C.A. The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model. Br. J. Pharmacol. 2006, 147:873-885.
37. Martinez J., Moreno J.J. Effect of resveratrol, a natural polyphenolic compound, on reactive oxygen species and prostaglandin production. Biochem. Pharmacol. 2000, 59:865-870.
38. Melgar S., Karlsson A., Michaëlsson E. Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 288:G1328-G1338.
39. Melgar S., Karlsson L., Rehnström E., Karlsson A., Utkovic H., Jansson L., Michaëlsson E. Validation of murine dextran sulfate sodium-induced colitis using four therapeutic agents for human inflammatory bowel disease. Int. Immunopharmacol. 2008, 8:836-844.
40. Pecchi E., Dallaporta M., Jean A., Thirion S., Troadec J.D. Prostaglandins and sickness behavior: old story, new insights. Physiol. Behav. 2009, 97:279-292.
41. Podolsky D.K. Inflammatory bowel disease (1). N. Engl. J. Med. 1991, 325:928-937.
42. Podolsky D.K. Inflammatory bowel disease (2). N. Engl. J. Med. 1991, 325:1008-1016.
43. Reagan-shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008, 22:659-661.
44. Rogler G., Andus T. Cytokines in inflammatory bowel disease. World J. Surg. 1998, 22:382-389.
45. Rojas-Cartagena C., Flores I., Appleyard C.B. Role of tumor necrosis factor receptors in an animal model of acute colitis. Cytokine 2005, 32:85-93.
46. Sánchez-Muñoz F., Dominguez-Lopez J., Yamamoto-Furusho K. Role of cytokines in inflammatory bowel disease. World J. Gastroenterol. 2008, 14:4280-4288.
47. Shakibaei M., Harikumar K.B., Aggarwal B.B. Resveratrol addiction: to die or not to die. Mol. Nutr. Food Res. 2009, 53:115-128.
48. Subbaramaiah K., Chung W.J., Michaluart P., Telang N., Tanabe T., Inoue H., Jang M., Pezzuto J.M., Dannenberg A.J. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J. Biol. Chem. 1998, 273:21875-21882.
49. Subbaramaiah K., Yoshimatsu K., Scherl E., Das K.M., Glazier K.D., Golijanin D., Soslow R.A., Tanabe T., Naraba H., Dannenberg A.J. Microsomal prostaglandin E synthase-1 is overexpressed in inflammatory bowel disease. Evidence for involvement of the transcription factor Egr-1. J. Biol. Chem. 2004, 279:12647-12658.
50. Sun M.J., Davaatseren M., Kim W., Park S.K., Kim S.H., Hur H.J., Kim M.S., Kim Y.S., Kwon D.Y. Vitisin A suppresses LPS-induced NO production by inhibiting ERK, p38, and NF-κB activation in RAW 264.7 cells. Int. Immunopharmacol. 2009, 9:319-323.
51. Waetzig G.H., Seegert D., Rosenstiel P., Nikolaus S., Schreiber S. p38 mitogen-activated protein kinase is activated and linked to TNF-alpha signaling in inflammatory bowel disease. J. Immunol. 2002, 168:5342-5351.
52. Walle T., Hsieh F., DeLegge M.H., Oatis J.E., Walle U.K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 2004, 32:1377-1382.
53. Wang X., Zhao L., Han T., Chen S., Wang J. Protective effects of 2, 3, 5, 4′-tetrahydroxystilbene-2-O-beta-D-glucoside, an active component of Polygonum multiflorum Thunb, on experimental colitis in mice. Eur. J. Pharmacol. 2008, 578:339-348.
54. Yang Y.T., Weng C.J., Ho C.T., Yen G.C. Resveratrol analog-3, 5, 4′-trimethoxy-trans-stilbene inhibits invasion of human lung adenocarcinoma cells by suppressing the MAPK pathway and decreasing matrix metalloproteinase-2 expression. Mol. Nutr. Food Res. 2009, 53:407-416.